Business Development & Finance Committee

Charter

The Business Development & Finance Committee (BDF) strives to:

• Address the evolving CGT business model and key considerations including clinical development, partnerships, financing, and commercialization.
  
  

Projects & Objectives

• The BDF champions the ISCT Investigators to Investors (I to I) program, which strives to bridge the knowledge gap between investigators and investors within the cell and gene therapy (CGT) sector. 
• Conducts bi-annual surveys with aim to understand investor perceptions of key opportunities and challenges in the CGT field at the time.
• Curates topical educational webinars, white papers and roadmaps to support decision-making in cell therapy manufacturing for both the investor and investigator profiles
• Develops roundtables for ISCT Annual and Regional meetings on topics related to Investment & Partnering Strategies
  
  

Ideal Member Profile

• Business development executives (e.g., CEOs, SVPs/VPs, etc.)
• Cell and Gene Therapy investors & analysts, by invitation
  
  

Selected Publications

• Cell and Gene Therapy Investment: Evolution and Future Outlook on Investor Perspectives (2024)
• Investor Perspective of Cell & Gene Therapy: A 2018 Snapshot (2021)
  
  

The Committee

Co-Chair

Sven Kili, MBChB, MRCS (Eng)

Sven Kili Consulting
Saisei Ventures
United Kingdom

Co-Chair

Patrick Rivers, MBA

aMoon Fund
United States

Members:

Dark Horse Consulting